<DOC>
	<DOCNO>NCT01163253</DOCNO>
	<brief_summary>The main objective study evaluate long-term safety CP-690,550 patient treat moderate severe chronic plaque psoriasis . This open label extension study available patient participate one qualify study CP-690,550 provide entry criterion meet .</brief_summary>
	<brief_title>A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description>The study terminate 08MAR2016 met objective characterize long term safety tolerability . The study terminate due safety concern .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Have participate qualify study CP690,550 18 year old diagnosis plaquetype psoriasis ( psoriasis vulgaris ) . Nonplaque drug induce form psoriasis ; Can discontinue current oral , injectable topical therapy psoriasis discontinue phototherapy ( PUVA UVB ) . Any uncontrolled significant medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>chronic</keyword>
	<keyword>severe</keyword>
	<keyword>treatment</keyword>
	<keyword>safety</keyword>
	<keyword>CP-690</keyword>
	<keyword>550</keyword>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>Psoriasis Vulgaris</keyword>
	<keyword>Xeljanz</keyword>
	<keyword>Tofacitinib</keyword>
</DOC>